Translational science by public biotechnology companies in the IPO "class of 2000": The impact of technological maturity

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  McNamee, Laura ^a   Ledley, Fred ^a  

^a BENTLEY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOTECHNOLOGICAL PRODUCTION; CAPITAL; COHORT ANALYSIS; ECONOMIC DEVELOPMENT; FINANCIAL DEFICIT; FUNDING; INVESTMENT; PIPELINE; PRODUCT DEVELOPMENT; TRANSLATIONAL RESEARCH;

BIOTECHNOLOGY; COMMERCE; HUMANS; INDUSTRY; ORGANIZATIONS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84893016105     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082195     Document Type: Article

References (19)

1. Munos BH (2009) Lessons from 60 years of pharmaceutical innovation. Nature Reviews Drug Discovery 8: 959-968.
2. Scannell JW, Blanckley A, Boldon H, Warrington B (2012) Diagnosing the decline in pharmaceutical R&D efficiency. Nature Reviews Drug Discovery 11: 191-200.
3. Pisano GP (2006) Science Business: The promise, the reality, and the future of biotech. Boston: Harvard Business School Press.
4. Booth BL (2009) Beyond the biotech IPO: a brave new world. Nature Biotechnology 27: 705-709.
5. Foster RN (1986) Innovation: The Attacker's Advantage. New York: Summit Books.
6. Christensen CM, Raynor ME (2003) The Innovator's Solution: Creating and Sustaining Successful Growth. Boston: Harvard Business School Press.
7. Johnson MW, Christensen CM, & Kagermann H (2008) Reinventing your business model. Harvard Business Review December: 58-68.
8. McNamee LM, Ledley FD (2012) Patterns of Technological Innovation in Biotechnology. Nat Biotechnol 30: 937-943.
9. Edwards M, Murray F, Yu R (2006) Gold in the ivory tower: equity rewards of outlicensing. Nature biotechnology 24: 509-516.
10. DiMasi JA, Feldman L, Seckler A, Wilson A (2010) Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther 87: 272-277.
11. Lehman Brothers, McKinsey & Co. (2001) The Fruits of Genomics. New York
12. Booth B, Zemmel R (2004) Prospects for productivity. Nat Rev Drug Discov 3: 451-456. (Pubitemid 38618127)
13. Chesbrough H, Rosenbloom RS (2002) The Role of the Business Model in Capturing Value from Innovation: Evidence from Xerox Corporation's Technology Spin Off Companies. Industrial and Corporate Change 11: 529-555. (Pubitemid 34703901)
14. Morris M, Schindehutte M, Allen J (2005) The entrepreneur's business model: toward a unified perspective. Journal of Business Research 58: 726-735. (Pubitemid 40105690)
15. Harper AR, Topol EJ (2012) Pharmacogenomics in clinical practice and drug development. Nature biotechnology 30: 1117-1124.
16. Sheridan C (2011) Gene therapy finds its niche. Nature Biotechnology 29: 121-128.
17. Guedj I, Scharfstein D (2004) Organizational scope and investment: Evidence from the drug development strategies of biopharmaceutical firms. NBER working paper.
18. Ledford H (2013) Biotech boom prompts fears of bust. Nature 500: 513.
19. Cockburn IM, Henderson RM (1998) Absorptive Capacity, Coauthoring Behavior, and the Organization of Research in Drug Discovery. Journal of Industrial Economics 46: 157-182.